

958	10.4	86.7	94	14	AAQ48049
959	10.4	86.7	94	18	AAQ90309
960	10.4	86.7	94	20	RAX51873
961	10.4	86.7	94	21	AAZ87725
962	10.4	86.7	94	22	RAF86860
963	10.4	86.7	94	22	ABX70202
964	10.4	86.7	94	25	ABX17639
965	10.4	86.7	95	14	AAQ48068
966	10.4	86.7	95	18	AAQ85862
967	10.4	86.7	95	18	AAQ65417
968	10.4	86.7	95	22	RAF86875
969	10.4	86.7	95	25	ABX17344
970	10.4	86.7	95	25	ABX17660
971	10.4	86.7	96	14	AAQ33886
972	10.4	86.7	96	21	AAZ87732
973	10.4	86.7	96	21	AAZ87737
974	10.4	86.7	96	21	AAZ46921
975	10.4	86.7	96	22	AAQ48565
976	10.4	86.7	96	22	AAQ70209
977	10.4	86.7	96	22	AAQ70214
978	10.4	86.7	96	25	AAQ51521
979	10.4	86.7	97	14	AAQ48072
980	10.4	86.7	97	15	AAQ44725
981	10.4	86.7	97	18	AAZ73618
982	10.4	86.7	97	20	AAZ228559
983	10.4	86.7	97	22	ABA74310
984	10.4	86.7	97	22	AAQ22776
985	10.4	86.7	97	22	AAQ48945
986	10.4	86.7	97	22	AAQ54773
987	10.4	86.7	97	23	ABS48611
988	10.4	86.7	97	25	ABX17664
989	10.4	86.7	98	21	AAQ60331
990	10.4	86.7	98	21	AAQ60332
991	10.4	86.7	98	22	AAQ75455
992	10.4	86.7	100	16	AAQ20394
993	10.4	86.7	100	18	AAQ73623
994	10.4	86.7	100	19	AAQ08056
995	10.4	86.7	100	20	AAQ06265
996	10.4	86.7	100	21	AAQ54861
997	10	83.3	12	23	AB178373
998	10	83.3	12	23	AB178374
999	10	83.3	13	14	AAQ52487
1000	10	83.3	13	15	AAQ67275

## ALIGNMENTS

RESULT 1	
AAQ77634	
ID	AAQ77634 standard; RNA; 18 BP.
QC	AAQ77634;
QC	
DT	25-MAR-2003 (updated)
DT	02-JUN-1995 (first entry)

XX Ribonucleotide to tenascin gene consensus mRNA initiation site -9+9.  
 XX Antisense; polynucleotide; sense strand; tenascin; complementary;  
 XX consensus; initiation; extracellular; glycoprotein; muscle; translati  
 XX proliferation; growth stimulatory; transcription; vascular stenosis;  
 XX post-angioplasty; restenosis; cardiac hypertrophy; vascular surgery;  
 XX organ transplant; ds.  
 XX Synthetic.  
 XX

CMX5-1 light chain  
Multiple cloning s  
Human secreted p  
Anti-human VEGF re  
Angiogenesis 100  
Ganglioside GD2 sp  
Ganglioside GD2 sp  
Anti-human Flt-1 a  
Modified rat DNA p  
Humanised antibody  
CDR-grafted heavy  
Transforming grow  
Ganglioside GD3 sp  
Modified ganglios  
Modified rat DNA p  
gfl variable domain  
Anti-human VEGF re  
Anti-human VEGF re  
gfl variable domain  
Ganglioside GD2 sp  
Anti-human Flt-1 a  
Anti-human Flt-1 a  
Human Nkd (hNkd) g  
Humanised antibody  
Oligonucleotide us  
Primer used in pre  
Oligonucleotide C2  
Oligonucleotide C2  
Human foetal liver  
Human brain expres  
Human bone marrow  
Probe #23459 used  
Human liver single  
Modified rat DNA p  
Primer Pvp1. Synt  
Primer Pvp2. Synt  
Codon-optimised Hp  
Human gene signatu  
Primer used in pre  
Fragment of gangli  
Primer 20265 for  
Human Pngl derived  
Oligonucleotide pr  
Oligonucleotide pr  
pING4533 kozak seq  
Consensus Kozak tr

MO9421664-A1.

23-SEP-1994.  
24-MAR-1994; 94WO-US03206.  
25-MAR-1993; 93US-0037025.  
(TEXAS-) TEXAS BIOTECHNOLOGY  
Denner LA, Dixon RAF, Regge  
WPI; 1994-316926/39.

Synthetic anti-sense polynucleotide - hybridises to tenascin gene, useful for inhibiting vascular smooth muscle cell proliferation.

Claim 5; Page 47; 64pp; English.

A series of polynucleotides, either DNA (AAQ76388 and AAQ76392-400 and AAQ76414-18) or RNA (AAQ76390 and AAQ76333-467), directed against the consensus mRNA initiation site sequence (AAQ77661) for the tensacin gene. The polynucleotides are based on the degenerate sequence (AAQ76386) of the tensacin gene. Tensacin is an extracellular matrix glycoprotein consisting six disulphide-linked subunits, each having molecular mass of 190-250 kDa. Tensacin may be important for smooth muscle cell proliferation as the protein has growth stimulatory activity. The polynucleotides can be used to inhibit transcription of the gene or translation of the mRNA encoding tensacin. The method is applicable to a number of diseases where the proliferation of smooth muscle is involved e.g. vascular stenosis, post-angioplasty restenosis and other non-angioplasty procedures such as cardiac hypertrophy, vascular surgery and organ transplant.

(Updated on 25-MAR-2003 to correct PN field.)

Sequence 18 BP; 2 A; 5 C; 8 G; 3 U; 0 other;

very Match 100.0%; Score 12; DB 15; Length 18;

Percent Local Similarity 85.5%; P-ED: NO: 2.8e+03;  
 Mismatches 10; Conservative 2; Mismatches 0; Indels 0; Gaps 0;

1 CCATGGTGGAGG 12

6 CCAUGGUGGAGG 17

## RESULT 2

AAQ77620/c  
ID AAQ77620 standard; DNA; 18 BP.

AAQ77620;

DT	25-MAR-2003	(updated)
DT	01-JUN-1995	(first entry)

Antisense polynucleotide binds to tenascin gene consensus at -9-+9.

Antisense; polynucleotide; sense strand; tenascin; complementary; consensus; initiation; extracellular; glycoprotein; muscle; translation; proliferation; growth stimulator; transcription; vascular stenosis; post-angioplasty; restenosis; cardiac hypertrophy; vascular surgery; organ transplant; ds.

Synthetic.

Key	Location/Qualifiers
100	100
101	101
102	102
103	103
104	104
105	105
106	106
107	107
108	108
109	109
110	110
111	111
112	112
113	113
114	114
115	115
116	116
117	117
118	118
119	119
120	120
121	121
122	122
123	123
124	124
125	125
126	126
127	127
128	128
129	129
130	130
131	131
132	132
133	133
134	134
135	135
136	136
137	137
138	138
139	139
140	140
141	141
142	142
143	143
144	144
145	145
146	146
147	147
148	148
149	149
150	150
151	151
152	152
153	153
154	154
155	155
156	156
157	157
158	158
159	159
160	160
161	161
162	162
163	163
164	164
165	165
166	166
167	167
168	168
169	169
170	170
171	171
172	172
173	173
174	174
175	175
176	176
177	177
178	178
179	179
180	180
181	181
182	182
183	183
184	184
185	185
186	186
187	187
188	188
189	189
190	190
191	191
192	192
193	193
194	194
195	195
196	196
197	197
198	198
199	199

29-SEP-1994.  
24-MAR-1994; 94WO-US03206.  
25-MAR-1993; 93US-0037025.  
(TEXA-) TEXAS BIOTECHNOLOGY CORP.  
Denner LA, Dixon RAP, Rege AA, Stacy DL;  
WPI; 1994-316926/39.  
Synthetic anti-sense polynucleotide - hybridises to tenascin  
gene, useful for inhibiting vascular smooth muscle cell  
proliferation.  
Claim 10; Page 44; 64pp; English.  
A series of antisense polynucleotides, either DNA (AAQ76388 and  
AAQ77619-32) or RNA (AAQ76390 and AAQ77647-60) directed against the sense  
strand of the gene encoding tenascin. The polynucleotides are based on  
the complementary sequence (AAQ76386) of the consensus mRNA initiation  
site sequence (AAQ77661) for the tenascin gene. Tenascin is an  
extracellular matrix glycoprotein consisting of six disulphide-linked  
subunits, each having molecular mass of 190-250 kDa. Tenascin may be  
important for smooth muscle cell proliferation as the protein has growth  
stimulatory activity. The polynucleotides can be used to inhibit  
transcription of the gene or translation of the mRNA encoding tenascin.  
The method is applicable to a number of diseases where the proliferation  
of smooth muscle is involved e.g. vascular stenosis, post-angioplasty  
restenosis and other non-angioplasty procedures such as cardiac  
hypertrophy, vascular surgery and organ transplant.  
(Updated on 25-MAR-2003 to correct PN field.)  
Sequence 18 BP; 3 A; 8 C; 5 G; 2 T; 0 other;  
Query Match 100.0%; Score 14; DB 15; Length 18;  
Best Local Similarity 100.0%; Pred. No. 4.8e+02;  
Matches 14; Conservative 0; Mismatches 0; Indels 0; Gaps 0;  
QY 1 CCCCATGGTGGAGG 14  
DB 15 CCCCATGGTGGAGG 2  
RESULT 3  
AAQ77648/C  
ID AAQ77648 standard; RNA; 18 BP.  
XX  
XX AAQ77648;  
XX  
XX 25-MAR-2003 (updated)  
XX 02-JUN-1995 (first entry)  
XX Antisense ribonucleotide binds to tenascin gene consensus at -9-+9.  
XX Antisense; polynucleotide; sense strand; tenascin; complementary;  
XX consensus; initiation; extracellular; glycoprotein; muscle; translation;  
XX proliferation; growth stimulatory; transcription; vascular stenosis;  
XX post-angioplasty; restenosis; cardiac hypertrophy; vascular surgery;  
XX organ transplant; ds.  
XX Synthetic.  
XX  
XX Key Location/Qualifiers  
XX misc\_difference 1..18  
XX /\*tag= a  
XX /note= "phosphodiester bonds between nucleotides  
XX may be replaced by phosphorothioate bonds"  
XX  
XX W09421664-A1.  
XX  
XX 29-SEP-1994.

29-SEP-1994.  
24-MAR-1994; 94WO-US03206.  
25-MAR-1993; 93US-0037025.  
(TEXA-) TEXAS BIOTECHNOLOGY CORP.  
Denner LA, Dixon RAP, Rege AA, Stacy DL;  
WPI; 1994-316926/39.  
Synthetic anti-sense polynucleotide - hybridises to tenascin  
gene, useful for inhibiting vascular smooth muscle cell  
proliferation.  
Claim 10; Page 51; 64pp; English.  
A series of antisense polynucleotides, either DNA (AAQ76388 and  
AAQ77619-32) or RNA (AAQ76390 and AAQ77647-60) directed against the sense  
strand of the gene encoding tenascin. The polynucleotides are based on  
the complementary sequence (AAQ76386) of the consensus mRNA initiation  
site sequence (AAQ77661) for the tenascin gene. Tenascin is an  
extracellular matrix glycoprotein consisting of six disulphide-linked  
subunits, each having molecular mass of 190-250 kDa. Tenascin may be  
important for smooth muscle cell proliferation as the protein has growth  
stimulatory activity. The polynucleotides can be used to inhibit  
transcription of the gene or translation of the mRNA encoding tenascin.  
The method is applicable to a number of diseases where the proliferation  
of smooth muscle is involved e.g. vascular stenosis, post-angioplasty  
restenosis and other non-angioplasty procedures such as cardiac  
hypertrophy, vascular surgery and organ transplant.  
(Updated on 25-MAR-2003 to correct PN field.)  
Sequence 18 BP; 3 A; 8 C; 5 G; 2 U; 0 other;  
Query Match 100.0%; Score 14; DB 15; Length 18;  
Best Local Similarity 100.0%; Pred. No. 4.8e+02;  
Matches 14; Conservative 0; Mismatches 0; Indels 0; Gaps 0;  
QY 1 CCCCATGGTGGAGG 14  
DB 15 CCCCATGGTGGAGG 2  
RESULT 4  
AAQ76393  
ID AAQ76393 standard; DNA; 18 BP.  
XX  
XX AAQ76393;  
XX  
XX 25-MAR-2003 (updated)  
XX 02-JUN-1995 (first entry)  
XX Polynucleotide to tenascin gene consensus mRNA initiation site -9-+9.  
XX Antisense; polynucleotide; sense strand; tenascin; complementary;  
XX consensus; initiation; extracellular; glycoprotein; muscle; translation;  
XX proliferation; growth stimulatory; transcription; vascular stenosis;  
XX post-angioplasty; restenosis; cardiac hypertrophy; vascular surgery;  
XX organ transplant; ds.  
XX Synthetic.  
XX  
XX Key Location/Qualifiers  
XX misc\_difference 1..18  
XX /\*tag= a  
XX /note= "phosphodiester bonds between nucleotides  
XX may be replaced by phosphorothioate bonds"  
XX  
XX W09421664-A1.  
XX  
XX 29-SEP-1994.

C 958 10.4 74.3 89 22 AAK44523  
 C 959 10.4 74.3 89 22 AAL50512  
 C 960 10.4 74.3 89 23 ABS44181  
 C 961 10.4 74.3 89 24 ABS18760  
 C 962 10.4 74.3 90 20 AAB87016  
 C 963 10.4 74.3 90 24 ABK36944  
 C 964 10.4 74.3 91 24 ABL74647  
 C 965 10.4 74.3 92 24 AD28212  
 C 966 10.4 74.3 94 21 AAO79989  
 C 967 10.4 74.3 94 22 AAC81526  
 C 968 10.4 74.3 94 25 AAL54302  
 C 969 10.4 74.3 95 24 ABV95815  
 C 970 10.4 74.3 99 21 ABA98099  
 C 971 10.2 72.9 20 21 AAC63973  
 C 972 10 71.4 10 21 AAC60401  
 C 973 10 71.4 10 21 AAA33090  
 C 974 10 71.4 10 22 AAD06402  
 C 975 10 71.4 10 22 AAH19564  
 C 976 10 71.4 10 24 ABK95227  
 C 977 10 71.4 10 24 AAS16881  
 C 978 10 71.4 14 20 AAV92785  
 C 979 10 71.4 15 24 AAS19541  
 C 980 10 71.4 17 25 ABZ62149  
 C 981 10 71.4 18 24 ABN89448  
 C 982 10 71.4 19 21 AAA98699  
 C 983 10 71.4 19 25 ABT31711  
 C 984 10 71.4 20 17 AAT16966  
 C 985 10 71.4 20 19 AAV29783  
 C 986 10 71.4 20 19 AAV22545  
 C 987 10 71.4 20 21 AAC59843  
 C 988 10 71.4 20 21 AAA90774  
 C 989 10 71.4 20 24 ABT95220  
 C 990 10 71.4 20 25 ABT32097  
 C 991 10 71.4 20 25 ABT31701  
 C 992 10 71.4 21 16 AAT79657  
 C 993 10 71.4 21 21 AAA14614  
 C 994 10 71.4 21 24 ABZ31021  
 C 995 10 71.4 21 24 ABZ51275  
 C 996 10 71.4 23 15 AAS58892  
 C 997 10 71.4 23 19 AAV17030  
 C 998 10 71.4 23 19 AAV16993  
 C 999 10 71.4 23 22 AAB78157  
 C1000 10 71.4 23 24 ABX00130

## ALIGNMENTS

RESULT 1  
 ID AAO77634 standard; RNA; 18 BP.  
 AC AAO77634;  
 XX  
 DT 25-MAR-2003 (updated)  
 DT 02-JUN-1995 (first entry)  
 XX  
 DE Ribonucleotide to tenascin gene consensus mRNA initiation site -9-+9.  
 XX  
 KW Antisense; polynucleotide; sense strand; tenascin; complementary;  
 KW consensus; initiation; extracellular; glycoprotein; muscle; translation;  
 KW proliferation; growth stimulatory; transcription; vascular stenosis;  
 KW post-angioplasty; restenosis; cardiac hypertrophy; vascular surgery;  
 KW organ transplant; ds.  
 XX  
 OS Synthetic.  
 XX  
 XX  
 FH Key Location/Qualifiers  
 FT misc\_difference 1..18  
 FT /\*tag= a  
 FT /note= "phosphodiester bonds between nucleotides  
 FT may be replaced by phosphorothioate bonds"  
 XX

Human bone marrow  
 Probe #19198 used  
 Human liver single  
 Human genome-deriv  
 Human single-nucle  
 Human DNA encoding  
 Corn tassels-derive  
 Plasmid primer-1 D  
 Vector pEGFP-N1 DN  
 Plasmid pEGFP-N1 f  
 DNA region of plas  
 Human pancreatic c  
 A. aeolicus lumazi  
 Icelandic scallop  
 Example translatio  
 Control sequence o  
 Translation initia  
 Translation initia  
 Translation initia  
 Translation initia  
 Human A-raf target  
 ASO primer #10 to  
 Human H-Ras DNAM  
 Human Znf12-Pc5  
 Nucleic acid combi  
 G protein coupled  
 Human/murine chima  
 PCR primer for bov  
 Antisense oligonuc  
 B. anthracis micro  
 Ribonucleotide red  
 Capture oligonucle  
 NOVA probe Seq ID  
 G protein coupled  
 Primer OTG5015 to  
 Sense PCR primer u  
 Candida albicans G  
 Human CADPKL DNA s  
 Alpha globin promo  
 GAPDH PCR primer K  
 GAPDH house-keepin  
 Nucleotide sequenc  
 Mouse MABL-2 scFv

PN WO9421664-A1.  
 XX  
 PD 29-SEP-1994.  
 XX  
 PF 24-MAR-1994; 94WO-0503206.  
 XX  
 PR 25-MAR-1993; 93US-0037025.  
 XX  
 PA (TEXA-) TEXAS BIOTECHNOLOGY CORP.  
 XX  
 PI Denner LA, Dixon RAF, Rege AA, Stacy DL;  
 DR WPI; 1994-316926/39.  
 XX  
 PT Synthetic anti-sense polynucleotide - hybridises to tenascin  
 PT gene, useful for inhibiting vascular smooth muscle cell  
 PT proliferation.  
 XX  
 PS Claim 5; Page 47; 64pp; English.  
 XX  
 CC A series of polynucleotides, either DNA (AAQ76388 and AAQ76392-400 and  
 CC AAQ77614-18) or RNA (AAQ76390 and AAQ77661) directed against the  
 CC consensus mRNA initiation site sequence (AAQ77661) for the tenascin gene.  
 CC The polynucleotides are based on the degenerate sequence (AAQ76386) of  
 CC the tenascin gene. Tenascin is an extracellular matrix glycoprotein  
 CC consisting of six disulphide-linked subunits, each having molecular mass of  
 CC 190-250 kDa. Tenascin may be important for smooth muscle cell  
 CC proliferation as the protein has growth stimulatory activity. The  
 CC polynucleotides can be used to inhibit transcription of the gene or  
 CC translation of the mRNA encoding tenascin. The method is applicable to a  
 CC number of diseases where the proliferation of smooth muscle is involved  
 CC e.g. vascular stenosis, post-angioplasty restenosis and other  
 CC non-angioplasty procedures such as cardiac hypertrophy, vascular surgery  
 CC and organ transplant.  
 CC (Updated on 25-MAR-2003 to correct PN field.)  
 XX  
 SQ Sequence 18 BP; 2 A; 5 C; 8 G; 3 U; 0 other;  
 XX  
 Query Match 100.0%; Score 14; DB 15; Length 18;  
 Best Local Similarity 85.7%; Pred. No. 3.9e+02;  
 Matches 12; Conservative 2; Mismatches 0; Indels 0; Gaps 0;  
 QY 1 GGGCCCCCATGTGG 14  
 |||||:|:|:|:  
 Db 1 GGGCCCCCAUGGUGG 14  
 RESULT 2  
 ID AAO77620/c  
 XX  
 AC AAO77620;  
 XX  
 DT 25-MAR-2003 (updated)  
 DT 01-JUN-1995 (first entry)  
 XX  
 DE Antisense polynucleotide binds to tenascin gene consensus at -9-+9.  
 XX  
 KW Antisense; polynucleotide; sense strand; tenascin; complementary;  
 KW consensus; initiation; extracellular; glycoprotein; muscle; translation;  
 KW proliferation; growth stimulatory; transcription; vascular stenosis;  
 KW post-angioplasty; restenosis; cardiac hypertrophy; vascular surgery;  
 KW organ transplant; ds.  
 XX  
 OS Synthetic.  
 XX  
 XX  
 FH Key Location/Qualifiers  
 FT misc\_difference 1..18  
 FT /\*tag= a  
 FT /note= "phosphodiester bonds between nucleotides  
 FT may be replaced by phosphorothioate bonds"  
 XX  
 PN WO9421664-A1.

C 958 11.2 65.9 53 13 AAQ29702  
 959 11.2 65.9 53 24 AAD28809  
 960 11.2 65.9 53 24 ABL31941  
 961 11.2 65.9 53 24 ABL31966  
 962 11.2 65.9 54 17 AAT42503  
 963 11.2 65.9 54 19 AAV41808  
 964 11.2 65.9 54 22 ABL32431  
 965 11.2 65.9 54 22 ABL31975  
 966 11.2 65.9 55 24 ABL31919  
 967 11.2 65.9 57 16 AAT25716  
 968 11.2 65.9 57 16 AAT24085  
 969 11.2 65.9 57 22 AAL02932  
 970 11.2 65.9 58 16 AAT23484  
 971 11.2 65.9 59 14 AAQ48344  
 972 11.2 65.9 59 14 AAQ47032  
 973 11.2 65.9 59 19 AAV30024  
 974 11.2 65.9 59 22 AAD21205  
 975 11.2 65.9 59 25 ABX96900  
 976 11.2 65.9 59 25 ABX80039  
 977 11.2 65.9 60 24 ABX96650  
 978 11.2 65.9 60 24 ABX96651  
 979 11.2 65.9 60 24 ABQ96109  
 980 11.2 65.9 60 24 ABN96436  
 981 11.2 65.9 60 24 ABN32585  
 982 11.2 65.9 60 24 ABN32925  
 983 11.2 65.9 60 24 ABN36580  
 984 11.2 65.9 60 24 ABN36976  
 985 11.2 65.9 60 24 ABN37924  
 986 11.2 65.9 60 24 ABN39985  
 987 11.2 65.9 60 24 ABN40204  
 988 11.2 65.9 60 24 ABN40863  
 989 11.2 65.9 60 24 ABN43625  
 990 11.2 65.9 60 24 ABN49041  
 991 11.2 65.9 60 24 ABN59120  
 992 11.2 65.9 62 24 AAD30991  
 993 11.2 65.9 62 24 AAD30980  
 994 11.2 65.9 63 21 AAZ32763  
 995 11.2 65.9 63 25 ABT21668  
 996 11.2 65.9 64 16 AAT22590  
 997 11.2 65.9 65 24 ABN28152  
 998 11.2 65.9 65 24 ABN30112  
 999 11.2 65.9 65 24 ABN54076  
 c1000 11.2 65.9 65 24 ABN58260

## ALIGNMENTS

RESULT 1  
 AAQ77634  
 ID AAQ77634 standard; RNA; 18 BP.  
 AC AAQ77634;  
 XX  
 XX  
 DT 25-MAR-2003 (updated)  
 DT 02-JUN-1995 (first entry)  
 XX

DE Ribonucleotide to tenascin gene consensus mRNA initiation site -9-+9.

XX Antisense; polynucleotide; sense strand; tenascin; complementary;  
 KW consensus; initiation; extracellular; glycoprotein; muscle; translation;  
 KW proliferation; growth stimulatory; transcription; vascular stenosis;  
 KW post-angioplasty; restenosis; cardiac hypertrophy; vascular surgery;  
 KW organ transplant; ds.

XX Synthetic.

XX Key Location/Qualifiers  
 XX misc\_difference 1..18  
 FT /\*tag= a  
 FT /note= "phosphodiester bonds between nucleotides  
 may be replaced by phosphorothioate bonds"

IRS-1 probe 80. S  
 Primer, T7VH used  
 PCR amplified DNA  
 FokI/FspI contain  
 Primer for preproH  
 Human pancreatic c  
 Empedobacter brevi  
 PCR amplified DNA  
 Target DNA oligonu  
 Human gene signatu  
 Human gene signatu  
 Human reproductive  
 Human gene signatu  
 MAB 25D2 light cha  
 HCV NS3/NS4 sequen  
 PCR primer used to  
 Sense PCR primer #  
 Hepatitis C virus  
 Hepatitis C virus  
 Human p53 gene oli  
 Human p53 gene oli  
 Tumour suppression  
 Kozak consensus mo  
 Human spliced tran  
 Human spliced tran  
 Human spliced tran  
 Human spliced tran  
 Human spliced tran  
 Human spliced tran  
 Human spliced tran  
 Human spliced tran  
 Human spliced tran  
 Human spliced tran  
 Bridging oligo #1  
 Bridging oligo #1  
 Chimeric antibody  
 Breast cancer mark  
 Human gene signatu  
 Rat spliced transc  
 Rat spliced transc  
 Mouse spliced tran  
 Mouse spliced tran

PN WO9421664-A1.  
 XX  
 XX 29-SEP-1994.  
 XX  
 XX 24-MAR-1994; 94WO-US03206.  
 XX 25-MAR-1993; 93US-0037025.  
 XX (TEXA-) TEXAS BIOTECHNOLOGY CORP.  
 PA Denner LA, Dixon RAF, Rege AA, Stacy DL;  
 FI WPI; 1994-316926/39.  
 XX  
 XX Synthetic anti-sense polynucleotide - hybridises to tenascin  
 gene, useful for inhibiting vascular smooth muscle cell  
 proliferation.

Claim 5; Page 47; 64pp; English.

CC A series of polynucleotides, either DNA (AAQ76388 and AAQ76392-400 and  
 CC AAQ77614-18) or RNA (AAQ76390 and AAQ77633-46), directed against the  
 CC consensus mRNA initiation site sequence (AAQ77661) for the tenascin gene.  
 CC The polynucleotides are based on the degenerate sequence (AAQ76386) of  
 CC the tenascin gene. Tenascin is an extracellular matrix glycoprotein  
 CC consisting of six disulphide-linked subunits, each having molecular mass of  
 CC 190-250 kDa. Tenascin may be important for smooth muscle cell  
 CC proliferation as the protein has growth stimulatory activity. The  
 CC polynucleotides can be used to inhibit transcription of the gene or  
 CC translation of the mRNA encoding tenascin. The method is applicable to a  
 CC number of diseases where the proliferation of smooth muscle is involved  
 CC e.g. vascular stenosis, post-angioplasty restenosis and other  
 CC non-angioplasty procedures such as cardiac hypertrophy, vascular surgery  
 CC and organ transplant.  
 CC (Updated on 25-MAR-2003 to correct PN field.)

XX SQ Sequence 18 BP; 2 A; 5 C; 8 G; 3 U; 0 other;

Query Match 100.0%; Score 17; DB 15; Length 18;  
 Best Local Similarity 88.2%; Pred. No. 56;  
 Matches 15; Conservative 2; Mismatches 0; Indels 0; Gaps 0;

Qy 1 GGCCCCCATGTCGAGG 17  
 |||||:|||||  
 Db 1 GGCCCCCAUGGUGAGG 17

RESULT 2  
 AAQ77620/c  
 ID AAQ77620 standard; DNA; 18 BP.  
 XX

AC AAQ77620;

XX 25-MAR-2003 (updated)

DT 01-JUN-1995 (first entry)

XX Antisense polynucleotide binds to tenascin gene consensus at -9-+9.

XX Antisense; polynucleotide; sense strand; tenascin; complementary;  
 KW consensus; initiation; extracellular; glycoprotein; muscle; translation;  
 KW proliferation; growth stimulatory; transcription; vascular stenosis;  
 KW post-angioplasty; restenosis; cardiac hypertrophy; vascular surgery;  
 KW organ transplant; ds.

XX Synthetic.

XX Key Location/Qualifiers  
 XX misc\_difference 1..18  
 FT /\*tag= a  
 FT /note= "phosphodiester bonds between nucleotides  
 may be replaced by phosphorothioate bonds"

PN WO9421664-A1.